Elewski et al. Supplementary data
Published: 16 February 2023| Version 1 | DOI: 10.17632/445r6ys4v4.1
Contributor:
James ParkinsonDescription
Supplementary material for the manuscript "Rapid and sustained improvements in GPPGA scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study" by Boni Elewski et al. 2023, Journal of the American Academy of Dermatology
Files
Steps to reproduce
Results from the Effisayil 1 study, a randomized, placebo-controlled study of spesolimab, an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis (GPP) flare. For study protocol see: Bachelez H, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med 2021;385:2431-40
Categories
Psoriasis, Clinical Trial Results
Funding
Boehringer Ingelheim